| __timestamp | ADMA Biologics, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 7890000 |
| Thursday, January 1, 2015 | 6745968 | 14456000 |
| Friday, January 1, 2016 | 8494742 | 19218000 |
| Sunday, January 1, 2017 | 18092835 | 27986000 |
| Monday, January 1, 2018 | 22502922 | 47928000 |
| Tuesday, January 1, 2019 | 25910757 | 96388000 |
| Wednesday, January 1, 2020 | 35050817 | 157743000 |
| Friday, January 1, 2021 | 42896889 | 195293000 |
| Saturday, January 1, 2022 | 52458024 | 237374000 |
| Sunday, January 1, 2023 | 59020000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustainable growth. Over the past decade, Blueprint Medicines Corporation and ADMA Biologics, Inc. have shown distinct trends in their SG&A expenditures. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600%, with expenses peaking at nearly $295 million in 2023. In contrast, ADMA Biologics experienced a more modest rise of approximately 1,100%, reaching around $59 million in the same year.
Blueprint Medicines' aggressive spending reflects its rapid expansion and investment in innovation, while ADMA Biologics' steadier growth suggests a more conservative approach. These trends highlight the diverse strategies within the biotech sector, where balancing cost management with growth ambitions is key to long-term success.
SG&A Efficiency Analysis: Comparing Novartis AG and ADMA Biologics, Inc.
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Walgreens Boots Alliance, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV